CAJ | 학술논문

目的：探究局部进展期乳腺癌新辅助化疗中应用磁共振灌注成像的疗效,并分析该方法作为化疗反应预测因子的可行性。方法12例乳腺癌患者依据新辅助化疗后肿瘤体积的改变分为效应组和无效应组,比较化疗前后最大信号丢失率、肿瘤体积的变化以及化疗前最大信号丢失率与肿瘤退缩率之间的相关性。结果化疗后,效应组的肿瘤平均体积(2.89±1.03) cm3,显著低于化疗前及无效应组化疗后肿瘤体积,差异有统计学意义(P<0.05)；效应组患者在接受新辅助化疗后,最大信号丢失率为(13±11.2)%,显著低于化疗前及无效应组化疗后相关指标。新辅助化疗一个疗程后,两组患者间的灌注最大信号丢失率改变的差异有统计学意义(P>0.05)。最大信号丢失率的平均值与肿瘤体积的退缩率之间呈正相关(r=0.313,P=0.44)。结论局部进展期乳腺癌辅助化疗可以应用磁共振灌注成像技术进行早期的评价,但需进一步深入的研究来佐证其是否可以作为化疗反应的预测因子。
목적：탐구국부진전기유선암신보조화료중응용자공진관주성상적료효,병분석해방법작위화료반응예측인자적가행성。방법12례유선암환자의거신보조화료후종류체적적개변분위효응조화무효응조,비교화료전후최대신호주실솔、종류체적적변화이급화료전최대신호주실솔여종류퇴축솔지간적상관성。결과화료후,효응조적종류평균체적(2.89±1.03) cm3,현저저우화료전급무효응조화료후종류체적,차이유통계학의의(P<0.05)；효응조환자재접수신보조화료후,최대신호주실솔위(13±11.2)%,현저저우화료전급무효응조화료후상관지표。신보조화료일개료정후,량조환자간적관주최대신호주실솔개변적차이유통계학의의(P>0.05)。최대신호주실솔적평균치여종류체적적퇴축솔지간정정상관(r=0.313,P=0.44)。결론국부진전기유선암보조화료가이응용자공진관주성상기술진행조기적평개,단수진일보심입적연구래좌증기시부가이작위화료반응적예측인자。
Objective To explore the clinical application of magnetic resonance imaging neoadjuvant chemotherapy of locally advanced breast cancer, and analyze the feasibility of the method as a predictor of response to chemotherapy. Methods 12 cases of patients with breast cancer after neoadjuvant chemotherapy on tumor volume change into effect group and ineffective group, the rate of change in tumor volume loss, maximum signal comparison before and after chemotherapy and chemotherapy before the maximum signal loss rate from a correlation between the rate and tumor. Results The effect of chemotherapy group, the average tumor volume of (2.89±1.03) cm3, significantly lower than that before chemotherapy and after chemotherapy the tumor volume of invalid should group, the difference was statistically significant (P<0.05);group effect in patients receiving neoadjuvant chemotherapy, the maximum signal loss rate was (13±11.2)%, significantly below before chemotherapy and after chemotherapy should be related to invalid index group. Neoadjuvant chemotherapy after a period of treatment, loss rate change perfusion maximum signal between two groups was statistically significant (P>0.05). There was a positive correlation between the shrinking rate of mean values of maximum signal loss rate and tumor volume (r=0.313, P=0.44). Conclusion Neoadjuvant chemotherapy of locally advanced breast cancer can be early evaluation of the application of magnetic resonance imaging technology, but need further study to prove whether it can be used as a predictor of response to chemotherapy.